



CM HOSPITALAR S.A.

Publicly Traded Company

Corporate Taxpayer's ID (CNPJ/MF) 12.420.164/0001-57

Company's Registry (NIRE) 35.300.486.854

CVM Code 25682

ISIN: BRVVEOACNOR0

B3 Ticker: VVEO3

MATERIAL FACT

CM Hospitalar S.A. ('Viveo' or 'the Company'), in compliance with applicable regulations, hereby advises stockholders and the market in general of its assessment of the potential synergies arising from the 17 (seventeen) acquisitions that Viveo has made in 2021 and 2022. Some of these¹ are still subject to conditions precedent, such as approval by the Brazilian antitrust authority, CADE (*Conselho Administrativo de Defesa Econômica*).

In its acquisitions, Viveo has focused on accelerating its strategy through the following growth drivers: (i) reinforcing its position in its core business; (ii) expanding its presence in, or entering, adjacent markets of high potential; and (iii) operating in new businesses areas to strengthen its ecosystem.

The synergies identified in Viveo's operations have the potential to generate value through operational leverage, expanded commercial strength and opportunities, and in terms of corporate structure. Viveo expects that the opportunities it has mapped will increase its Ebitda, mainly due to optimization of costs and general and administrative expenses.

The projections presented below will be included in Section 11 of the Company's Reference Form, which will be available, within the legal period, on the *Empresas.Net* system, at the websites of the CVM (Brazilian Securities Commission) (<https://sistemas.cvm.gov.br/>) and the São Paulo stock exchange (*B3 – Brasil, Bolsa, Balcão* (<http://b3.com.br/>), and also on Viveo's Investor Relations site (<https://ri.viveo.com.br/>).

1. Projections of synergy gains

¹ AzimuteMed, Life, PHD, Proinfusion and Famap. The acquisition of Famap does not require CADE authorization.

The acquisitions made, and the subjects of these projections, are:

M&A	Item
Profarma Specialty	Distributor of medications to hospitals and clinics; provider of delivery services to specialized pharmacies; patient support programs.
FW and Daviso	Manufacturers of wet wipes.
Tecno 4 and Pointmed	Distributors of medical materials
Medcare and BEMK	Distributors of medical materials
Cirúrgica Mafra	Specialized pharmaceutical products: physical stores and delivery.
Apijã, Macromed and Laborsys	Distributors of reagents to the <i>Laboratories</i> channel.
Boxifarma	Unitizing services; delivery of medications; pharmaceutical monitoring/accompaniment.
Life, Famap and ProInfusion	Compounding and handling of sterile solutions.
PHD	Distributor of medical materials.
Azimute Med	Provider of patient support services.

As from 2022, Viveo expects, gradually, to capture **synergies that will increase recurring Ebitda by BRL 111 million (in real numbers, base date 12/31/2021)** in the activities shown in the above table, as a result of:

- (i) Reduction of costs, due to optimization of purchasing, logistics, fiscal aspects, and industrial operations.
- (ii) Reduction of general and administrative expenses.

Additionally, an increase in revenues from commercial synergies was mapped, from cross-selling and sales levers by the ecosystem itself, which can generate additional synergies, not included in this value.

The estimated amounts of synergies do not include expenses and capex for the implementation of mapped actions.

2. Estimated timetable for capture of synergies

Viveo expects to capture the synergies derived from the acquisitions, as from 2022. Viveo has created this timetable to ensure that the acquired companies are integrated without any loss of quality in services or internal controls. Usually, the administrative synergies are captured more quickly, and synergies that involve capex on plant develop a little more slowly. The following is Viveo's estimated timetable:

2022: BRL 12 million

2023: BRL 67 million

2024: BRL 32 million

3. Assumptions and metrics for the projections

The figures for capture of synergies assume that the Company will succeed in implementing the following initiatives, among others:

- Reduction of costs, from optimization of the logistics network and tax organization.
- Reduction of administrative expenses, from unification of processes and increase in operational efficiency.
- Renegotiation with direct and indirect suppliers for optimization of resources and operations.
- Optimization of the production chain and increased efficiency in production of consumer goods.
- Increase in retail and services operations, and in products and services offered to the final consumer.

Ribeirão Preto, June 7, 2022

Flávia Carvalho
Investor Relations and M&A Officer
CM HOSPITALAR S.A.